Brentuximab vedotin is a medication used to treat certain types of lymphoma (cancer of the lymphatic system). It works by targeting specific proteins on cancer cells to help destroy them. In this trial, it is being studied as a maintenance therapy for patients who have received an allogeneic hematopoietic stem cell transplant (a procedure where a patient receives blood-forming stem cells from a donor) for cutaneous T-cell lymphomas, which are cancers that affect the skin.

Graft-versus-host disease (GVHD) – A condition that occurs after bone marrow transplantation where the donor’s immune cells attack the recipient’s tissues. GVHD can develop in two forms: acute, which typically occurs within 100 days after transplant, and chronic, which develops later. The condition primarily affects the skin, liver, and digestive system. The immune cells from the donor recognize the recipient’s body as foreign and launch an immune response against these tissues.

Cutaneous T-cell lymphoma – A rare type of cancer that begins in white blood cells called T-cells and primarily affects the skin. The disease causes red, scaly patches or thickened plaques of skin that may be itchy. As it progresses, these skin lesions can become more widespread across the body. The condition develops slowly, often starting with dry, itchy patches that can be mistaken for other skin conditions.